• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Do Cuong V bought 10,000 shares (SEC Form 4)

    3/6/24 5:12:41 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DO CUONG V

    (Last) (First) (Middle)
    C/O BIOVIE INC.
    680 W NYE LANE STE 201

    (Street)
    CARSON CITY NV 89703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIOVIE INC. [ BIVI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/04/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock 03/04/2024 P 10,000 A (1) 435,854 I See Footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants (right to buy) $1.5 03/04/2024 P 5,000 03/04/2024 03/04/2029 Common Stock 5,000 (1) 5,000 I See Footnote(2)
    Explanation of Responses:
    1. The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $1.00 in connection with the issuer's public offering that closed on March 6, 2024.
    2. Securities are held in the name of Do & Rickles Investments LLC.
    /s/ Cuong V Do 03/06/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

      Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"

      5/15/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

      CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson's disease on Wednesday, May 28, 2025 at 12:00 PM ET. To re

      5/14/25 7:30:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioVie Inc.

      SC 13G - BIOVIE INC. (0001580149) (Subject)

      10/25/24 4:01:25 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioVie Inc.

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      6/25/24 7:47:33 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      3/10/23 5:15:43 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioVie Inc.

      10-Q - BIOVIE INC. (0001580149) (Filer)

      5/12/25 5:15:33 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by BioVie Inc.

      PRE 14A - BIOVIE INC. (0001580149) (Filer)

      5/8/25 5:20:30 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14C filed by BioVie Inc.

      PRE 14C - BIOVIE INC. (0001580149) (Filer)

      5/7/25 5:20:08 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Do Cuong V bought 10,000 shares (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      3/6/24 5:12:41 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      12/1/23 6:26:32 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

      Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

      7/22/22 7:51:28 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on BioVie with a new price target

      B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

      11/30/21 8:23:48 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:26:37 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:24:53 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:21:05 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Financials

    Live finance-specific insights

    See more

    $BIVI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

      Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"

      5/15/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

      CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson's disease on Wednesday, May 28, 2025 at 12:00 PM ET. To re

      5/14/25 7:30:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

      CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

      6/4/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces the Appointment of a New Chief Medical Officer

      RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

      11/1/21 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care